These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 22292444

  • 1. Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy.
    Nowsheen S, Whitley AC, Yang ES.
    Curr Mol Med; 2012 Jul 01; 12(6):788-803. PubMed ID: 22292444
    [Abstract] [Full Text] [Related]

  • 2. Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways.
    Aziz K, Nowsheen S, Georgakilas AG.
    Curr Mol Med; 2010 Oct 01; 10(7):626-39. PubMed ID: 20712589
    [Abstract] [Full Text] [Related]

  • 3. Non-homologous DNA end joining in anticancer therapy.
    Pastwa E, Malinowski M.
    Curr Cancer Drug Targets; 2007 May 01; 7(3):243-50. PubMed ID: 17504121
    [Abstract] [Full Text] [Related]

  • 4. Targeting BER enzymes in cancer therapy.
    Visnes T, Grube M, Hanna BMF, Benitez-Buelga C, Cázares-Körner A, Helleday T.
    DNA Repair (Amst); 2018 Nov 01; 71():118-126. PubMed ID: 30228084
    [Abstract] [Full Text] [Related]

  • 5. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
    Lamberti G, Andrini E, Sisi M, Federico AD, Ricciuti B.
    Future Oncol; 2020 Aug 01; 16(23):1751-1766. PubMed ID: 32539551
    [Abstract] [Full Text] [Related]

  • 6. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches.
    Dietlein F, Thelen L, Reinhardt HC.
    Trends Genet; 2014 Aug 01; 30(8):326-39. PubMed ID: 25017190
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
    Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM.
    Clin Cancer Res; 2016 Dec 01; 22(23):5651-5660. PubMed ID: 27678458
    [Abstract] [Full Text] [Related]

  • 9. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer.
    Velic D, Couturier AM, Ferreira MT, Rodrigue A, Poirier GG, Fleury F, Masson JY.
    Biomolecules; 2015 Nov 20; 5(4):3204-59. PubMed ID: 26610585
    [Abstract] [Full Text] [Related]

  • 10. DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy.
    de Almeida LC, Calil FA, Machado-Neto JA, Costa-Lotufo LV.
    Cancer Genet; 2021 Apr 20; 252-253():6-24. PubMed ID: 33340831
    [Abstract] [Full Text] [Related]

  • 11. DNA repair proteins as molecular targets for cancer therapeutics.
    Kelley MR, Fishel ML.
    Anticancer Agents Med Chem; 2008 May 20; 8(4):417-25. PubMed ID: 18473726
    [Abstract] [Full Text] [Related]

  • 12. DNA Repair Endonucleases: Physiological Roles and Potential as Drug Targets.
    Doherty R, Madhusudan S.
    J Biomol Screen; 2015 Aug 20; 20(7):829-41. PubMed ID: 25877151
    [Abstract] [Full Text] [Related]

  • 13. Targeting DNA damage response kinases in cancer therapy.
    Gottifredi V.
    Mutat Res; 2020 Aug 20; 821():111725. PubMed ID: 33157476
    [Abstract] [Full Text] [Related]

  • 14. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.
    Arjumand W, Asiaf A, Ahmad ST.
    Methods Mol Biol; 2018 Aug 20; 1699():3-21. PubMed ID: 29086365
    [Abstract] [Full Text] [Related]

  • 15. Molecular markers for cancer prognosis and treatment: have we struck gold?
    Nowsheen S, Aziz K, Panayiotidis MI, Georgakilas AG.
    Cancer Lett; 2012 Dec 31; 327(1-2):142-52. PubMed ID: 22120674
    [Abstract] [Full Text] [Related]

  • 16. [Impairment of DNA damage response and cancer].
    Rancoule C, Vallard A, Guy JB, Espenel S, Sauvaigo S, Rodriguez-Lafrasse C, Magné N.
    Bull Cancer; 2017 Nov 31; 104(11):962-970. PubMed ID: 29132683
    [Abstract] [Full Text] [Related]

  • 17. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
    Gao D, Herman JG, Guo M.
    Oncotarget; 2016 Jun 14; 7(24):37331-37346. PubMed ID: 26967246
    [Abstract] [Full Text] [Related]

  • 18. Bufalin induces cell death in human lung cancer cells through disruption of DNA damage response pathways.
    Wu SH, Wu TY, Hsiao YT, Lin JH, Hsu SC, Hsia TC, Yang ST, Hsu WH, Chung JG.
    Am J Chin Med; 2014 Jun 14; 42(3):729-42. PubMed ID: 24871662
    [Abstract] [Full Text] [Related]

  • 19. Predictive biomarkers for cancer therapy with PARP inhibitors.
    Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G.
    Oncogene; 2014 Jul 24; 33(30):3894-907. PubMed ID: 24037533
    [Abstract] [Full Text] [Related]

  • 20. Targeting the DNA Damage Response in Cancer.
    O'Connor MJ.
    Mol Cell; 2015 Nov 19; 60(4):547-60. PubMed ID: 26590714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.